

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 950)

PROPOSED ADOPTION OF AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION

References are made to the announcements of Lee's Pharmaceutical Holdings Limited (the "**Company**") dated 6 April 2022 and 19 May 2022.

Pursuant to the Consultation Conclusions on Listing Regime for Overseas Issuers published by The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") in November 2021, the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**") have been amended with effect from 1 January 2022 which requires, among others, listed issuers to adopt the "Core Standards" for shareholder protections as provided in the amended Appendix 3 to the Listing Rules. The board of directors of the Company (the "**Board**") proposes to take this opportunity to update the memorandum and articles of association of the Company and adopt an amended and restated memorandum and articles of association of the Company (the "**Amended and Restated M&A**") with regards to the updates in Listing Rules and the applicable laws, and to allow general meetings of the Company to be held as a physical meeting, hybrid meeting or an electronic meeting. At the upcoming annual general meeting of the Company, a special resolution will be proposed for the Shareholders to consider and, if thought fit, approve the proposed adoption of the Amended and Restated M&A incorporating amendments made for the purposes of, among others, (i) bringing the Amended and Restated M&A in line with amendments to Listing Rules and applicable laws of the Cayman Islands; (ii) to allow general meetings of the Company to be held as a physical meeting, hybrid meeting or an electronic meeting; and (iii) making certain minor housekeeping amendments for the purpose of clarifying existing practice and making consequential amendments in line with the proposed amendments in the Amended and Restated M&A.

* *For identification purpose only*

Details of the Amended and Restated M&A, together with the notice of the annual general meeting will be set out in the circular for the upcoming annual general meeting of the Company to be despatched to the Shareholders.

By order of the Board
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 17 April 2023

As at the date thereof, Ms. Lee Siu Fong (Chairman) and Ms. Leelalertsuphakun Wanee are executive Directors; Dr. Li Xiaoyi and Mr. James Charles Gale are non-executive Directors; Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive Directors.